Incyte’s promising thrombocythemia drug; Crescent Biopharma raises $200M in PIPE

Plus, news about D&D Pharmatech and Jasper Therapeutics: Incyte’s thrombocythemia win: The company’s antibody INCA033989, which targets and reduces cells with mutant calreticulin (mutCALR), allowed “rapid and durable” normalization of platelet counts in patients with ...

Related Posts

Reproductive health biotech ReproNovo closes $65M Series A

May 21, 2025  0

Where to Buy Quality Used Acura Engines in Florida

May 12, 2025  0

Altos Labs buys anti-aging startup Dorian Therapeutics

May 21, 2025  0

Comments

Name

Email

Comment

Post Comment